Emerging evidence suggests that low IGF-1 levels in obese individuals may increase the risk of nonalcoholic fatty liver disease, metabolic syndrome, and insulin resistance [15,18,19]. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatotic liver disease.